Windtree Therapeutics Equity Warrants Exp 25th March 2026 WINTW:OTCPK

*Data is delayed | Exchange | USD
Last | 04/23/24 EDT
0.0009UNCH (UNCH)
52 week range
0.00 - 0.03
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0009
  • 52 Week High0.03
  • 52 Week High Date10/23/23
  • 52 Week Low0.00
  • 52 Week Low Date03/25/24

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0009
  • 52 Week High0.03
  • 52 Week High Date10/23/23
  • 52 Week Low0.00
  • 52 Week Low Date03/25/24
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Windtree Therapeutics Equity Warrants Exp 25th March 2026

 

Profile

MORE
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, pre-clinical SERCA2a activators for heart failure and VAR-101 and VAR-102, pre-clinical precision atypical protein kinase C iota (aPKCi)...
Craig Fraser
Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial Officer
Eric Curtis
Chief Operating Officer, Senior Vice President
Jamie Mcandrew
Chief Accounting Officer, Vice President, Controller
Address
2600 Kelly Rd Ste 100
Warrington, PA
18976-3652
United States